Key Takeaways
- Jim Cramer cautioned viewers about jumping into stocks with “parabolic” momentum, particularly in the tech and AI sectors
- He recommended focusing on undervalued, out-of-favor companies instead of hot names
- Cramer’s Charitable Trust purchased Johnson & Johnson during a selloff
- He named J&J his top pharmaceutical stock for 2025, surpassing Eli Lilly in his rankings
- Cramer emphasized the importance of balancing hot and cold stocks in a diversified portfolio
On Monday’s episode of Mad Money, CNBC host Jim Cramer delivered a clear message to investors: resist the temptation to chase surging stocks and instead focus on quality companies that the market has temporarily abandoned.
Cramer warned that stocks experiencing “parabolic” rallies—particularly in the technology and artificial intelligence spaces—pose significant risks for buyers who enter late. He admitted that when he personally attempts to profit from these extreme moves, the results are typically disappointing.
“Those are all too hot, hot, hot for me,” Cramer remarked when discussing high-momentum semiconductor and AI-related stocks.
Rather than pursuing popular names like Intel or Advanced Micro Devices, Cramer revealed he’s taking the contrarian approach. He’s actively accumulating shares of well-established companies that have experienced sharp declines and lost investor enthusiasm.
His CNBC Investing Club Charitable Trust recently added Johnson & Johnson to its holdings while the stock continued to slide. The healthcare sector has been the S&P 500’s worst performer so far this year.
“We are buying it in freefall,” Cramer explained. “You don’t get to buy the best at a discount very often. When you do, you buy some.”
Cramer’s Bull Case for Johnson & Johnson
Cramer revealed that Johnson & Johnson has claimed the top spot in his pharmaceutical holdings, displacing Eli Lilly from that position. He pointed to the company’s robust drug development pipeline and strategic business restructuring as key drivers behind his bullish outlook.
The healthcare giant has been systematically divesting underperforming business units and concentrating resources on pharmaceutical innovation. Johnson & Johnson currently has numerous compounds in advanced clinical trials and has secured several regulatory approvals recently.
According to Cramer, the recent stock weakness stems primarily from market overreaction, especially regarding ongoing talc litigation. He believes these legal concerns have distracted investors from the company’s fundamental operational improvements.
Cramer also noted a recurring pattern with Johnson & Johnson’s earnings releases. The stock frequently drops when financial results are initially published in the morning, but rebounds once management hosts its conference call. “If it gets blasted, try to get some,” he advised.
Why Portfolio Balance Matters
Cramer used this opportunity to discuss broader portfolio construction principles. He cautioned that concentrating holdings exclusively in trending sectors creates vulnerability when market sentiment inevitably shifts.
“Your portfolio always needs to have a decent mix between what’s hot and what’s not,” he stated.
When specific market segments lose momentum, maintaining positions in undervalued, overlooked stocks ensures that some portfolio components continue performing. Cramer traced this strategy back to lessons he learned during his time at Goldman Sachs.
“They don’t all go up at once. To which I always said, but something should go up.”
Healthcare stocks have faced substantial headwinds throughout 2025. Johnson & Johnson shares have declined over the trailing twelve months, with the stock dropping approximately 1.57% in recent trading sessions as broader sector weakness persists.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
